Detalhe da pesquisa
1.
A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma.
Neuro Oncol
; 24(10): 1673-1686, 2022 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35213727
2.
Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase.
Mol Cancer Ther
; 19(8): 1623-1635, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32430484
3.
Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.
Cancer Cell
; 36(5): 545-558.e7, 2019 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31668947
4.
MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models.
Oncotarget
; 9(14): 11592-11603, 2018 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29545922
5.
The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
Clin Cancer Res
; 21(24): 5563-77, 2015 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26228206
6.
The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Response.
Clin Cancer Res
; 22(10): 2595, 2016 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27179114